Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Current Assets (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Current Assets for 11 consecutive years, with $21.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets rose 99.21% to $21.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $21.7 million, a 99.21% increase, with the full-year FY2024 number at $22.0 million, up 28.58% from a year prior.
  • Current Assets was $21.7 million for Q3 2025 at Marker Therapeutics, up from $14.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $67.5 million in Q1 2021 to a low of $10.9 million in Q3 2024.
  • A 5-year average of $26.6 million and a median of $21.7 million in 2025 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: crashed 64.82% in 2023, then soared 99.21% in 2025.
  • Marker Therapeutics' Current Assets stood at $46.0 million in 2021, then plummeted by 63.86% to $16.6 million in 2022, then increased by 3.06% to $17.1 million in 2023, then increased by 28.58% to $22.0 million in 2024, then fell by 1.31% to $21.7 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Current Assets are $21.7 million (Q3 2025), $14.8 million (Q2 2025), and $17.0 million (Q1 2025).